Pilot Study of ORG 25935 Modulation of Ketamine-induced Behavioral and Cognitive Effects in Healthy Male Subjects



Status:Active, not recruiting
Conditions:Healthy Studies
Therapuetic Areas:Other
Healthy:No
Age Range:18 - 55
Updated:1/11/2019
Start Date:December 2006
End Date:December 2019

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
Org 25935 is a new putative antipsychotic agent developed by N.V. Organon.The primary
objective of this study is to investigate the effect of Org 25935 on ketamine-induced
impairments in immediate recall.


Inclusion Criteria:

- Male, 18 - 55 years

Exclusion Criteria:

- History of sensitivity/idiosyncrasy to the drugs used in the study or chemically
related compounds or excipients which may be employed in the study or to any other
unknown drug used in the past.
We found this trial at
1
site
Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine
West Haven, Connecticut 06516
?
mi
from
West Haven, CT
Click here to add this to my saved trials